Specialty distributor handle distribution to smaller specialty pharmacies and retail pharmacies.
It is common for each specialty pharmaceutical product to have its own go-to-market strategy. Because of the unique specialty drug product specifications, therapy regimens, drug product handling, storage and transportation requirements, pricing, reimbursement and other factors, drug distribution channels and methodologies are impacted and must be considered prior to product launch. Specialty drugs do not necessarily flow directly downstream to the patient via the dispensing pharmacist. Pharmacy benefit-controlled specialty drugs can be more tightly controlled in real time, improving the payers’ ability to track utilization.
Specialty drugs are produced by specialty pharmaceutical manufacturers then sent to specialty distributors or large specialty pharmacies. From there, they may be distributed directly to patients or be sent to retail pharmacies. Specialty drugs play an increasingly important role in the treatment of chronic conditions such as multiple sclerosis (MS), rheumatoid arthritis (RA), psoriasis, and inflammatory bowel disease (IBD), etc.
According to our (Global Info Research) latest study, the global Specialty Drug Distribution market size was valued at USD 275360 million in 2022 and is forecast to a readjusted size of USD 541540 million by 2029 with a CAGR of 10.1% during review period. The influence of COVID-19 and the Russia-Ukraine War were considered while estimating market sizes.
Global Specialty Drug Distribution key players include Amerisource, Mckesson, Cardinal Health, PHOENIX group, etc.
North America is the largest market, with a share about 55%, followed by Europe, and Asia-Pacific, both have a share over 35 percent.
In terms of product, Oncology is the largest segment, with a share over 50%. And in terms of application, the largest application is Hospital and Clinics, followed by Pharmacy, etc.
Request free sample report or place an order @ https://www.globalinforesearch.com/reports/1000340/specialty-drug-distribution
This report is a detailed and comprehensive analysis for global Specialty Drug Distribution market. Both quantitative and qualitative analyses are presented by company, by region & country, by Type and by Application. As the market is constantly changing, this report explores the competition, supply and demand trends, as well as key factors that contribute to its changing demands across many markets. Company profiles and product examples of selected competitors, along with market share estimates of some of the selected leaders for the year 2023, are provided.
Market segment by Type
Oncology
Rheumatoid Arthritis
Multiple Sclerosis
Hemophilia
Others
Market segment by Application
Hospital and Clinic
Pharmacy
Others
Market segment by players, this report covers
AmerisourceBergen
Mckesson
Cardinal Health
Phoenix
Medipal Holdings
Alliance Healthcare
Sinopharm
Express Scripts
Shanghai Pharma
Anda
Jointown
Max Pharma
The content of the study subjects, includes a total of 15 chapters:
Chapter 1, to describe Specialty Drug Distribution product scope, market overview, market estimation caveats and base year.
Chapter 2, to profile the top manufacturers of Specialty Drug Distribution, with price, sales, revenue and global market share of Specialty Drug Distribution from 2018 to 2023.
Chapter 3, the Specialty Drug Distribution competitive situation, sales quantity, revenue and global market share of top manufacturers are analyzed emphatically by landscape contrast.
Chapter 4, the Specialty Drug Distribution breakdown data are shown at the regional level, to show the sales quantity, consumption value and growth by regions, from 2018 to 2029.
Chapter 5 and 6, to segment the sales by Type and application, with sales market share and growth rate by type, application, from 2018 to 2029.
Chapter 7, 8, 9, 10 and 11, to break the sales data at the country level, with sales quantity, consumption value and market share for key countries in the world, from 2017 to 2022.and Specialty Drug Distribution market forecast, by regions, type and application, with sales and revenue, from 2024 to 2029.
Chapter 12, market dynamics, drivers, restraints, trends, Porters Five Forces analysis, and Influence of COVID-19 and Russia-Ukraine War.
Chapter 13, the key raw materials and key suppliers, and industry chain of Specialty Drug Distribution.
Chapter 14 and 15, to describe Specialty Drug Distribution sales channel, distributors, customers, research findings and conclusion.
Research Data Source:
Primary and secondary research as two components of methodology applied: Primary research is based on online and telephone based survey, i.e. interviews with several key experts with different functions in the market – from industry, trade and customers, associations and external experts such as researchers. Secondary research is based on all kinds of publicly or commercially available sources, such as publications and further information published from industry (annual reports, company websites, press releases, industry journals and trade publications), relevant databases (government, patent, statistics, markets), scientific and technical writings for product information, scientific articles, and further paid data sources.
This study is based on analysis of information obtained continually since 2016 through our research regarding this industry, but updated through the recent months of 2022. During this period, our analysts performs interviews with authoritative and representative individuals in this industry, industry associations, import/export, and other. The interviews were conducted principally with:
- Manufactuers and their competitors
- Distributors, wholesaler, and agents
- Customers
- CEOs/ Marketing Executives
- Business Heads
- Industry Experts
- Technology and Innovation Directors
- Senior Managers
- Program/Project Directors
A full review of published information was also performed to supplement information obtained through interviews. The following sources were reviewed:
- Professional technical journals and papers
- Trade press articles
- Technical conference proceedings
- Product literature
- Company profile and financial information
- Additional information based on previous Global Info Research market studies
- Personal knowledge of the research team.
Contact US
Global Info Research
E-mail: report@globalinforesearch.com
Tel: +86-17665052062 00852-58197708(HK)
WeChat: 17665052062
Add:FLAT/RM A 9/F SILVERCORP INTERNATIONAL TOWER 707-713 NATHAN ROAD MONGKOK KL HONG KONG
Website: http://www.globalinforesearch.com
